Tumor-Associated Macrophages in Canine Oral and Cutaneous Melanomas and Melanocytomas: Phenotypic and Prognostic Assessment.
CD163
CD204
Iba1
MAC387
dogs
melanoma
tumor-associated macrophages
tumor-associated macrophages (TAMs)
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
02
2022
accepted:
22
06
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
The tumor microenvironment is a complex system, where neoplastic cells interact with immune and stromal cells. Tumor-associated macrophages (TAMs) are considered among the most numerically and biologically noteworthy cellular components in tumors and the attention on this cellular population has been growing during the last decade, both for its prognostic role and as a potential future therapeutic target. Melanoma, particularly the oral form, despite being one of the most immunogenic tumors, bears a poor prognosis in dogs and humans, due to its highly aggressive biological behavior and limited therapeutic options. The aims of this study are to characterize and quantify TAMs (using CD163, CD204, Iba1, and MAC387) in canine melanocytic tumors and to evaluate the association of these markers with diagnosis, histologic prognostic features, presence of metastases, and outcome, and to provide preliminary data for possible future therapies targeting TAMs. Seventy-two melanocytic tumors (27 oral melanomas, 25 cutaneous melanomas, 14 cutaneous melanocytomas, and 6 oral melanocytomas) were retrospectively selected and submitted to immunohistochemistry and double immunofluorescence. Double immunolabeling revealed that most CD163
Identifiants
pubmed: 35937296
doi: 10.3389/fvets.2022.878949
pmc: PMC9355725
doi:
Types de publication
Journal Article
Langues
eng
Pagination
878949Informations de copyright
Copyright © 2022 Porcellato, Sforna, Lo Giudice, Bossi, Musi, Tognoloni, Chiaradia, Mechelli and Brachelente.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Melanoma Res. 2017 Jun;27(3):200-210
pubmed: 28272106
Cell Mol Life Sci. 2019 Apr;76(8):1447-1458
pubmed: 30747250
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Vet Immunol Immunopathol. 2021 Dec;242:110337
pubmed: 34715601
Am J Pathol. 2011 May;178(5):2121-35
pubmed: 21514427
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
Equine Vet J. 2006 Jan;38(1):23-7
pubmed: 16411582
Crit Rev Immunol. 2014;34(3):241-61
pubmed: 24941076
Vet Sci. 2019 Feb 12;6(1):
pubmed: 30759787
Cell Mol Immunol. 2020 Jan;17(1):1-12
pubmed: 31611651
Vet Pathol. 2022 Jan;59(1):39-45
pubmed: 34547936
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
J Cell Mol Med. 2021 Jul;25(14):6909-6924
pubmed: 34096171
Vet Sci. 2021 Nov 02;8(11):
pubmed: 34822634
J Clin Cell Immunol. 2015 Jun;6(3):
pubmed: 26500805
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Mod Pathol. 2020 Aug;33(8):1458-1465
pubmed: 32291396
Vet Comp Oncol. 2020 Dec;18(4):727-738
pubmed: 32323423
Front Vet Sci. 2021 Aug 16;8:707025
pubmed: 34485435
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Vet Sci. 2021 Nov 22;8(11):
pubmed: 34822659
Front Immunol. 2021 Sep 03;12:716504
pubmed: 34539650
Biochem Biophys Res Commun. 2001 Aug 17;286(2):292-7
pubmed: 11500035
Vet Pathol. 2019 Mar;56(2):180-188
pubmed: 30244658
Front Immunol. 2019 Jul 03;10:1462
pubmed: 31333642
Nat Med. 2020 Dec;26(12):1865-1877
pubmed: 33077955
J Immunother Cancer. 2019 Dec 5;7(1):343
pubmed: 31806053
Vet Pathol. 2019 Mar;56(2):189-199
pubmed: 30381008
Int J Mol Sci. 2018 Mar 10;19(3):
pubmed: 29534457
Int J Exp Pathol. 2006 Jun;87(3):163-76
pubmed: 16709225
Vet Pathol. 2021 May;58(3):491-502
pubmed: 33764216
J Neuropathol Exp Neurol. 2020 Feb 1;79(2):184-193
pubmed: 31846038
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Melanoma Res. 2019 Jun;29(3):237-247
pubmed: 30399061
Vet Pathol. 2011 Jan;48(1):54-72
pubmed: 21266721
Int J Mol Sci. 2018 Jan 30;19(2):
pubmed: 29385676
Animals (Basel). 2020 Aug 17;10(8):
pubmed: 32824521
Animals (Basel). 2021 Mar 04;11(3):
pubmed: 33806407
J Comp Pathol. 2009 Jul;141(1):17-26
pubmed: 19362315
Pigment Cell Melanoma Res. 2014 Jan;27(1):90-102
pubmed: 24112648
J Pathol. 2020 Sep;252(1):4-21
pubmed: 32652526
Vet Pathol. 2021 Jan;58(1):42-52
pubmed: 33021155
Oncoimmunology. 2017 May 26;6(9):e1333213
pubmed: 28932635
Res Vet Sci. 2021 May;136:32-38
pubmed: 33582312
Pigment Cell Melanoma Res. 2014 Jan;27(1):37-47
pubmed: 24128326
Vet Pathol. 2021 Sep;58(5):952-963
pubmed: 34196247
PLoS One. 2015 Jul 21;10(7):e0133552
pubmed: 26197470
Vet Pathol. 2021 Sep;58(5):881-889
pubmed: 33685309
Biomolecules. 2020 Jul 22;10(8):
pubmed: 32707850
Am J Surg Pathol. 2004 Jan;28(1):31-40
pubmed: 14707861
Animals (Basel). 2020 Dec 09;10(12):
pubmed: 33316917
Animals (Basel). 2021 Aug 04;11(8):
pubmed: 34438760
Trends Immunol. 2019 Apr;40(4):310-327
pubmed: 30890304
Sci Rep. 2020 Feb 25;10(1):3360
pubmed: 32099066
Neurooncol Adv. 2021 May 04;3(1):vdab031
pubmed: 34286275
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752088
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Circulation. 2011 Dec 20;124(25):2920-32
pubmed: 22144572